Adipocytic Glutamine Synthetase Upregulation
chemoresistance
colorectal cancer
glutamine synthetase
histone methylation
peritoneal carcinomatosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
07
2021
accepted:
22
09
2021
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
30
10
2021
Statut:
epublish
Résumé
The development of resistance to 5-fluorouracil (5FU) chemotherapy is a major handicap for sustained effective treatment in peritoneal carcinomatosis (PC) of colorectal cancer (CRC). Metabolic reprogramming of adipocytes, a component of the tumor microenvironment and the main composition of peritoneum, plays a significant role in drug resistance of PC, with the mechanisms being not fully understood. By performing metabolomics analysis, we identified glutamine (Gln), an important amino acid, inducing resistance to 5FU-triggered tumor suppression of CRC-PC through activating mTOR pathway. Noteworthily, genetic overexpression of glutamine synthetase (GS) in adipocytes increased chemoresistance to 5FU
Identifiants
pubmed: 34712612
doi: 10.3389/fonc.2021.748730
pmc: PMC8547656
doi:
Types de publication
Journal Article
Langues
eng
Pagination
748730Informations de copyright
Copyright © 2021 Zhang, Li, Du, Li, Shi, Chen, Zhao, Wang and Pan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Jun;159(2):166-77
pubmed: 26001024
J Hematol Oncol. 2019 Jul 5;12(1):71
pubmed: 31277692
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Semin Cancer Biol. 2019 Dec;59:92-111
pubmed: 31408724
Hum Gene Ther. 2016 Mar;27(3):267-77
pubmed: 26756933
Pharmacol Ther. 2019 Mar;195:162-171
pubmed: 30439456
Trends Pharmacol Sci. 2019 Jun;40(6):419-429
pubmed: 31078320
Ann Surg. 1993 Jun;217(6):655-66; discussion 666-7
pubmed: 8099476
Oncogene. 2020 Feb;39(8):1681-1695
pubmed: 31705064
Cancer Sci. 2020 Sep;111(9):3142-3154
pubmed: 32536012
Blood. 2016 Aug 4;128(5):667-79
pubmed: 27268090
Pharmacol Res. 2020 May;155:104741
pubmed: 32151679
Cancer Biol Ther. 2010 Oct 15;10(8):788-95
pubmed: 20686362
Int J Mol Sci. 2018 Oct 25;19(11):
pubmed: 30366466
Neoplasia. 2004 Nov-Dec;6(6):813-20
pubmed: 15720808
Aging (Albany NY). 2020 Jul 29;12(14):14990-15001
pubmed: 32726297
Int J Biochem Cell Biol. 2009 Oct;41(10):2051-61
pubmed: 19703661
Cancer Lett. 2019 Dec 28;467:29-39
pubmed: 31574293
Cancer Epidemiol. 2014 Aug;38(4):448-54
pubmed: 24841870
Trends Cancer. 2017 Mar;3(3):169-180
pubmed: 28393116
Breast Cancer Res. 2015 Aug 19;17:112
pubmed: 26286584
Apoptosis. 2008 Feb;13(2):213-23
pubmed: 18158623
Cancer Res. 1994 Nov 15;54(22):5974-80
pubmed: 7954430
Blood. 2019 Sep 26;134(13):1014-1023
pubmed: 31416801
Cell Oncol (Dordr). 2020 Dec;43(6):989-1001
pubmed: 32474853
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021 Feb 25;50(1):32-40
pubmed: 34117847
Cancer Res. 2009 Oct 1;69(19):7867-74
pubmed: 19773440
Br J Cancer. 2020 Aug;123(3):459-470
pubmed: 32439934
Mol Plant. 2020 Aug 3;13(8):1194-1202
pubmed: 32585190
Cancer Chemother Pharmacol. 2003 Dec;52(6):465-8
pubmed: 12920569
Cell. 1974 Oct;3(2):127-33
pubmed: 4426090
World J Gastroenterol. 2019 Apr 21;25(15):1854-1864
pubmed: 31057299
Mol Cancer. 2008 Jan 25;7:14
pubmed: 18221502
Science. 2008 Jun 13;320(5882):1496-501
pubmed: 18497260
Curr Drug Targets. 2019;20(12):1217-1226
pubmed: 31215384
Mol Cancer. 2017 Feb 16;16(1):39
pubmed: 28209170
Nature. 2018 Sep;561(7721):63-69
pubmed: 30158707
JPEN J Parenter Enteral Nutr. 1991 Mar-Apr;15(2):159-64
pubmed: 1675697
Int J Mol Sci. 2021 Jun 23;22(13):
pubmed: 34201429
Cell Rep. 2017 Aug 15;20(7):1654-1666
pubmed: 28813676
Cell Metab. 2018 Jul 03;28(1):104-117.e5
pubmed: 29861385
Mol Cancer. 2006 May 18;5:20
pubmed: 16709241
Int J Cancer. 2011 Jun 1;128(11):2717-25
pubmed: 20715167
Br J Cancer. 2013 Apr 16;108(7):1432-9
pubmed: 23511564
Cells. 2019 Aug 08;8(8):
pubmed: 31398937
PLoS One. 2019 Jul 31;14(7):e0220360
pubmed: 31365553
Cell. 2017 Jul 27;170(3):548-563.e16
pubmed: 28753429
Surgery. 1997 Aug;122(2):451-63; discussion 463-4
pubmed: 9288153
Cold Spring Harb Perspect Biol. 2016 Apr 01;8(4):a019521
pubmed: 27037415
Front Cell Dev Biol. 2021 Mar 30;9:633259
pubmed: 33859984
Theranostics. 2018 Oct 29;8(19):5452-5468
pubmed: 30555557
Oncotarget. 2021 Jun 22;12(13):1256-1270
pubmed: 34194623
Breast Cancer Res. 2015 Apr 24;17:57
pubmed: 25908175
Cancer Res. 2020 Apr 15;80(8):1748-1761
pubmed: 32054768
Nat Commun. 2018 Apr 30;9(1):1739
pubmed: 29712898
Sci Rep. 2016 Jan 05;6:18923
pubmed: 26729407
Gastroenterology. 1994 May;106(5):1312-20
pubmed: 7909780
Nat Rev Mol Cell Biol. 2013 Mar;14(3):133-9
pubmed: 23361334
J Biol Chem. 2017 Jan 6;292(1):196-204
pubmed: 27879318
Cells. 2020 Jul 25;9(8):
pubmed: 32722384
Updates Surg. 2016 Mar;68(1):7-11
pubmed: 27067591
Neoplasia. 2020 Jan;22(1):22-32
pubmed: 31765939
Clin Exp Pharmacol Physiol. 2016 Aug;43(8):723-37
pubmed: 27097837
J Clin Invest. 2019 Jul 2;129(8):3006-3017
pubmed: 31264969
J Exp Clin Cancer Res. 2018 Nov 12;37(1):274
pubmed: 30419950
Expert Rev Proteomics. 2005 Oct;2(5):719-29
pubmed: 16209651
Clin Pharmacokinet. 2010;49(2):71-87
pubmed: 20067334
Oncogene. 2018 Apr;37(17):2285-2301
pubmed: 29398710
Am J Physiol Gastrointest Liver Physiol. 2002 Nov;283(5):G1062-73
pubmed: 12381519